|
Susceptibilities of common mycoplasma strains to antibiotics
S=susceptible; R=resistant; M=marginal response; S/R=mixed response
| M. pneumoniae (respiratory tract) |
| S minocycline |
S erythromycin |
| S doxycycline |
R cephalosporins |
| S difloxacin |
S clarithromycin |
| S azithromycin |
S/R clindamycin |
| S/R ciprofloxacin |
|
| M hominis (genitourinary tract) |
| S minocycline |
R erythromycin |
| S doxycycline |
S cephalosporins |
| M difloxacin |
R clarithromycin |
| S azithromycin |
S clindamycin |
| S ciprofloxacin |
|
| U urealticum (genitourinary tract) |
| S minocycline |
S erythromycin |
| S doxycycline |
S temafloxacin |
| S/R difloxacin |
S/R clarithromycin |
| S/R azithromycin |
R clindamycin |
| S/R ciprofloxacin |
|
| M fermentans (incognitis) (genito-urinary tract & oropharynx) |
| S minocycline |
R erythromycin |
| S doxycycline |
S temafloxacin |
| ? difloxacin |
? clarithromycin |
| ? azithromycin |
S clindamycin |
| S ciprofloxacin |
|
Some mycoplasmas, such as M. hominis and U urealticum are often found together and they each are resistant to the antibiotic which eliminates the other.
Usual colony site locations can also be helpful in choosing an effective dose of antibiotic as some sites take a higher dose than others.
Commercial mycoplasma test kits often give a false positive result and are not recommended.
A negative test is not unusual at the start of treatment. A second test approximately 4 weeks later often gives a positive result.
References
1 J. Travis, Microbial Trigger for Autoimmunity? Science News, June 21, 1997, Vol 151, 380.
2 see Journal Article list available from The Road Back Foundation, 4985 N Lake Hill Dr., Delaware OH 43015, USA.
3 J L Lin, Human Mycoplasmal Infections: Serologic Observations, Rev of Infec Dis, 1985; 7:2, 216-230
4 SA Poulon, RE perkins, RB Kundsin, Antibiotic susceptibilities of AIDS-associated mycoplasmas, J Clin Micro, 1994; 32:4, 1101-1103.
5 KB Waites, GH Cassell, KC Canupp, PB Fernandes, In Vitro susceptibilities of Mycoplasmas & Ureaplasmas to new macrolides and aryl-flouroquinolones, Antimicrob Agents and Chemo, 1988; 32:10, 1500-1502.
|
